Mortality trends era antiretroviral therapy evidence Network Analysing Longitudinal Population based HIVAIDS data Africa ALPHA Georges Reniersa Emma Slaymakera Jessica NakiyingiMiirob Constance Nyamukapac Amelia Catharine Crampinad Kobus Herbste Mark Urassaf Fred Otienog Simon Gregsonch Maquins Seweg Denna Michaelf Tom Lutaloi Victoria Hosegoodej Ivan Kasambab Alison Pricead Dorean Nabukalui Estelle Mcleana Basia Zabaa behalf ALPHA Network Background The rollout antiretroviral therapy ART largest public health interventions Eastern Southern Africa recent years Its impact described clinical cohort studies populationbased evidence rare Methods We use data seven demographic surveillance sites conduct communitybased HIV testing collect information uptake HIV services We present crude death rates adults aged 1564 period 20002011 sex HIV status treatment status Parametric survival models estimate age adjusted trends mortality rates people living HIV PLHIV introduction ART Results The pooled ALPHA Network dataset contains 24 million personyears followup time 39114 deaths 6893 PLHIV The mortality rates PLHIV relatively static availability ART Mortality declined rapidly typical declines 10 20 annum Compared pre ART era total decline mortality rates PLHIV exceeds 58 study sites available data amounts 84 women Masaka Uganda Mortality declines larger women men result statistically signiﬁcant ﬁve sites Apart early phase treatment scale mortality PLHIV ART high mortality declines observed PLHIV ART Conclusion The expansion treatment large pervasive effect adult mortality Mortality declines pronounced women factor attributed womens greater engagement HIV services Improvements timing ART initiation contributed mortality reductions PLHIV ART aDepartment Population Health London School Hygiene Tropical Medicine London UK bResearch Unit AIDS Medical Research CouncilUganda Virus Research Institute Entebbe Uganda cManicaland HIVSTD prevention project Bio medical Research Training Institute Harare Zimbabwe dKaronga Prevention Study London School Hygiene Tropical Medicine Chilumba Malawi eAfrica Centre Health Population Studies University KwaZulu Natal Somkhele South Africa fTAZAMA project National Institute Medical Research Mwanza Tanzania gKenya Medical Research Institute Centers Disease Control Prevention Kisumu Kenya hSchool Public Health Faculty Medicine Imperial College London UK iRakai Health Sciences Program Makerere University School Public Health Rakai Uganda jDepartment Social Statistics Demography Southampton University Southampton UK Correspondence Georges Reniers Email georgesrenierslshtmacuk Received 22 September 2014 revised 22 September 2014 accepted 22 September 2014 DOI101097QAD0000000000000496 ISSN 02699370 Q 2014 Wolters Kluwer Health Lippincott Williams Wilkins This openaccess article distributed terms Creative Commons AttributionNonCommercialNoDerivatives 40 License permissible download share work provided properly cited The work changed way commercially S533 S534 AIDS 2014 Vol 28 Suppl 4 started treatment increasingly selected early stage disease cid1 2014 Wolters Kluwer Health Lippincott Williams Wilkins AIDS 2014 28 Suppl 4S533S542 Keywords antiretroviral therapy ART HIV mortality subSaharan Africa surveillance Introduction The expansion HIV care treatment services largest public health interventions subSaharan Africa recent times notoriously difﬁcult evaluate populationwide impact countries hardest hit epidemic poor registration vital events Clinical cohort studies ﬁll information gap suggest mortality levels patients start treatment early default approaches HIVnegative individuals age 13 Clinical studies shown late presentation patient attrition continue limit efﬁcacy ART 35 The true mortality associated magnitude phenomena harder Intensive patient tracing studies shed light mortality patients lost followup 6 estimating mortality HIV positives contact health remains intractable clinicbased study designs estimate This situation calls populationbased assessment mortality trends contribution use data seven demographic HIV surveillance sites eastern southern African countries Several studies previously reported impact HIV adult mortality 712 This study differs earlier analyses data range extended 2011 covers years ART locally available We use individuallylinked information HIV testing treatment uptake allows estimate mortality trends people living HIV PLHIV disaggregate estimates treatment status Most estimates presented men women separately Gender equity uptake ART concern early days treatment scale initially womens elevated HIV prevalence concerns men privileged access treatment places offered patient copay scheme 1314 Current programme statistics suggest opposite gender disparity nationally representative surveys Africa consistently report higher female HIV Testing Counseling HTC coverage rates 15 disproportionately large number women ART compared estimated need sexes likely enroll 1617 Women advanced disease tend lower attrition mortality rates following treatment initiation 1721 Methods ALPHA Network study sites data Data study come seven members Network Analysing Longitudinal Populationbased HIVAIDS data Africa httpalphalshtmacuk located countries shown Fig 1 ALPHA Network study sites cover populations ranging 20 000 200 000 size With exception Manicaland study individuals consist residents set noncontiguous areas chosen represent distinct socioeconomic zones surveillance sites exhaustively cover entire population circumscribed area Demographic information col lected regular censuses generally conducted Masaka Kisumu Rakai Kisesa Karonga Manicaland uMkhanyakude Fig 1 Location ALPHA Network sites contributing data study We use location names refer study sites Other names Kisesa Magu Demographic Surveillance System Kisumu Kenya Medical Research InstituteCenters Disease Control Preven tion KEMRICDC HDSS Masaka General Population Cohort Kyamulibwa subdistrict uMkhanyakude Africa Centre Demographic Information System ACDIS Mortality trends antiretroviral therapy era Africa Reniers et al S535 interviews senior household member acts proxy respondent behalf household Prepopulated lists household members census round ﬁeldworker inquire residency survival status household residents In Karonga village informants assist demo graphic surveillance 22 The size study sites intervals demographic surveillance carried vary sites bearing range analyses possible sites data precision resulting estimates Along demographic surveillance ALPHA members organize postmortem interviews relatives deceased residents verbal autopsies repeated populationbased HIV serosurveys home visits mobile HIV testing centers residents invited HIV testing protocols participation rates varied time sites Prior availability rapid HIV tests treatment residents referred medical facility vicinity return test results directed separate testing counseling service In recent serosurveys ALPHA Network studies residents opportunity receive standard HTC visit specimens research test collected The serosurveys use individual interviews collect behavioral data including information utilization HIV AIDS care services The demographic surveillance data study continuously updated dataset analysis assembled September 2014 spans period 20002011 covers years introduction ART Several study sites started HIV surveys later demographic sur veillance HIV status information restricted narrower time span The date ranges overall mortality estimates mortality estimates HIV status stipulated study site ﬁrst column Table 1 Most ALPHA Network members published cohort proﬁles detailed descrip tions population characteristics ﬁeldwork procedures 2225 cases methodo logical studies describing HIV serosurveys non response rates associated bias HIV prevalence estimates 2627 Our measure exposure time risk dying comes residence episodes men women Table 1 Sitespeciﬁc characteristics study populations HIVRHIVS mortality rate ratios Study site country Individuals personyears deaths HIV status Mortality rates RR Dates allcause mortality Dates mortality HIV Average HIVa HIV status Individuals ages 1564 Person years Karonga MAW 20032011 20062011 Kisesa TAZ 20002011 20002011 Kisumu KEN 20032011 20082011 Manicaland ZIM 20002010 20002010 Masaka UGA 20002011 20002011 Rakai UGA 20002010 20002010 113 59 246 219 94 125 uMkhanyakude RSA 354 20012011 20042011 Total 185 All HIVcid1 HIVþ HIV unknownb All HIV HIVþ HIV unknownb All HIV HIVþ HIV unknownb All HIV HIVþ HIV unknownb All HIV HIVþ HIV unknownb All HIVcid1 HIVþ HIV unknownb All HIVcid1 HIVþ HIV unknownb All HIVcid1 HIVþ HIV unknownb 30 397 17 156 1761 29 384 45 540 18 192 1507 40 018 229 177 68 128 13 901 222 641 67 225 28 330 6604 59 060 21 999 17 342 1873 11 221 67 909 34 331 5538 59 194 88 230 26 294 12 314 87 791 550 477 209 773 43 498 509 309 144 479 47 204 5320 91 955 171 619 82 108 4750 84 761 901 590 110 874 32 153 758 564 319 384 99 621 29 861 189 903 105 860 81 138 7753 16 970 296 723 148 308 20 493 127 922 467 619 76 450 37 565 353 603 2407275 645 704 137 894 1623 677 20002003 20092011 Death rate 1000 HIVþHIV RR 95 CI Death rate 1000 HIVþHIV RR 95 CI 146 ND ND ND 125 91 769 123 256 ND ND ND 168 47 585 168 164 106 900 141 169 45 962 185 227 74 699 227 194 67 778 210 ND 84 67107 ND 123 101151 85 7102 212 182246 95 44206 116 107127 76 53 208 108 80 70 369 74 150 124 323 143 72 43 281 57 107 86 227 149 92 34 225 138 164 151 360 115 129 95 316 122 39 3051 53 3873 26 2428 65 5086 26 1936 66 5088 24 2127 33 3135 Deaths 1486 230 149 1107 1791 697 275 819 17 289 1369 1752 14 168 3908 579 1406 1923 1412 772 390 250 3668 559 1210 1899 9560 791 1711 7058 39 114 4997 6893 27 224 CI conﬁdence interval KEN Kenya MAW Malawi ND data RR rate ratio RSA South Africa TAZ Tanzania UGA Uganda ZIM Zimbabwe aAverage HIV prevalence ¼ HIVþ personyearsHIVþ personyears þ HIVcid1 personyears These prevalence estimates relatively high include HIV status information medical facilities treatment clinics increases fraction known HIV positives dataset bHIV unknown includes personsyears exposure start HIV surveillance study site individual time prior ﬁrst HIV test S536 AIDS 2014 Vol 28 Suppl 4 clinic community records study areas nature terminating events residence episodes administrative censoring death migration HIV status information comes com munitybased serological surveys supplemented self reports proxy reports postmortem interviews recordlinkage health facilities residents The important source retrieving data uptake treatment A ALPHA Network members established reliable record linkage demographic surveillance medical facility data unique identiﬁers common individuals Karonga Masaka uMkhanyakude Kisumu piloted probabilistic record linkage To allocate persontime HIV status treatment categories adopted set rules censoring HIV status service use information Individuals report HIVnegative followed HIVpositive test assumed seroconverted midpoint negative ﬁrst positive test dates allocate HIVpositive HIVnegative exposure time accordingly Persons HIV positive time ﬁrst HIV test observed exposure time following test classiﬁed HIV positive To calculate mortality HIVnegative individuals remain uninfected study classify exposure time tests HIV negative Following negative test classiﬁed HIV negative period time corresponding 95 probability age group remaining uninfected given site sexspeciﬁc HIV incidence rates Following cutoff point HIV status considered unknown Time lived individuals prior ﬁrst recorded HIV test classiﬁed HIV status unknown We classify individuals having received ART date ﬁrst recorded receiving treatment No attempt account treatment adherence interruption cessation Statistical methods We ﬁrst present trends allcause mortality rates adults aged 1564 sex HIV status treatment status This followed parametric survival analysis HIV positives mortality hazards individual age radix exact age 15 serves measure time Among possible distributions outcome Weibull model describes mortality patterns increase steadily age chosen basis Akaikes Information Criterion statistic values model ﬁt efﬁciency Hazard ratio estimates Weibull models qualitatively different semiparametric survival analysis supports choice Weibull distribution Under proportional hazards speciﬁcation Weibull model given set covariates Xj agespeciﬁc mortality hazard given hðagetjXj ¼ ptpcid11expðb0 þ XjbXÞ p represents change mortality age In application expect p 1 implies hazard monotone increasing age As covariates consider calendar year sex interaction To investigate changes mortality HIV positives following introduction ART ﬁt separate models preART post ART period coefﬁcients calendar year quantify impact ART average annual change mortality hazard HIVpositive adults In postART period allow mortality rates HIVpositive men women differ treatment status The representation calendar time dichotomous variables captures period treatment started locally available subsequent years This distinction ﬁrst years treatment rollout feature uncharacteristically highmortality rates backlog patients severe immunosuppression quickly ushered treatment The case Kisumu special service ART provision severely affected violence started presidential elections 27 December lasted truce signed 28 February 2008 28 Kisumu areas heavily implicated protests ruling government excess mortality associated protest introduced 2007 Given declining incidence trends observed surveys expected increases longevity treatment general lengthening duration postinfection PLHIV postART period However known seroconverters duration post infection measured constitute 12 PLHIV pooled dataset practical introduce duration postinfection metric exposure Results The pooled dataset contains 550477 individuals exact ages 15 65 43498 known HIV positive status jointly contribute 24 million personyears follow time 39114 deaths 6893 PLHIV A sitespeciﬁc breakdown statistics given Table 1 This table contains crude mortality rates rate ratios HIVpositive HIVnegative mortality period 20002003 ART available sites period 20092011 ART locally available study sites These provide indication mortality reductions taken place rollout ART In early 2000s HIVþHIVcid1 mortality rate ratios varied 84 Kisesa 95 conﬁdence interval CI 67107 212 Rakai 95 CI 182246 Mortality trends antiretroviral therapy era Africa Reniers et al S537 Between 2009 2011 rate ratios ranged 24 uMkhanyakude 95 CI 2127 66 Rakai 95 CI 5088 Figures 2 3 provide detailed descriptions trends mortality rates HIV status treatment status The background shading illustration marks years ART locally introduced 2004 2007 depending site years rollout completed 2005 2009 In online appendix present mortality estimates study site sex HIV status selected calendar years Karonga Kisesa 0 0 0 1 r e p e t R 0 0 2 0 5 1 0 0 1 0 5 0 0 0 0 1 r e p e R t 0 0 2 0 5 1 0 0 1 0 5 0 0 0 0 1 r e p e t R 0 0 0 1 r e p e t R 0 0 2 0 5 1 0 0 1 0 5 0 0 0 2 0 5 1 0 0 1 0 5 0 0 0 0 1 r e p e t R 0 0 2 0 5 1 0 0 1 0 5 0 2000 2002 2004 2006 2008 2010 Calendar Year 2000 2002 2004 Calendar Year 2006 2008 2010 Kisumu Manicaland 0 0 0 1 r e p e R t 0 0 2 0 5 1 0 0 1 0 5 0 2000 2002 2004 Calendar Year 2006 2008 2010 2000 2002 2004 Calendar Year 2006 2008 2010 Masaka Rakai 0 0 0 1 r e p e R t 0 0 2 0 5 1 0 0 1 0 5 0 2000 2002 2006 2004 Calendar Year 2008 2010 2000 2002 2006 2004 Calendar Year 2008 2010 uMkhanyakude 2000 2002 2004 Calendar Year 2006 2008 2010 ART intro HIV Men HIV Men ART HIV Women HIV Women Fig 2 Allcause death rates 95 conﬁdence intervals study site HIV status sex ages 1564 S538 AIDS 2014 Vol 28 Suppl 4 Karonga Kisumu 0 0 0 1 r e p e R t 0 0 0 1 r e p e R t 0 0 2 0 5 1 0 0 1 0 5 0 0 0 2 0 5 1 0 0 1 0 5 0 0 0 0 1 r e p e R t 0 0 2 0 5 1 0 0 1 0 5 0 2000 2002 2004 2006 2008 2010 2000 2002 2004 2006 2008 2010 Calendar Year Calendar Year Masaka Rakai 0 0 0 1 r e p e R t 0 0 2 0 5 1 0 0 1 0 5 0 2000 2002 2004 2006 2008 2010 2000 2002 2004 2006 2008 2010 Calendar Year Calendar Year uMkhanyakude 0 0 0 1 r e p e t R 0 0 2 0 5 1 0 0 1 0 5 0 2000 2002 2004 2006 2008 2010 Calendar Year ART intro No record ART ART Had ART Fig 3 Allcause death rates 95 conﬁdence intervals PLHIV study site treatment status ages 1564 sexes In instance estimates conﬁdence intervals truncated modiﬁed maintain readability plots This affects following estimates Kisumu 2008 ART 528 95 conﬁdence interval CI 374747 Masaka 2004 ART 204 95 CI 106392 uMkhanyakude 2005 ART 139 95 CI 77251 Insufﬁcient treatment uptake data Kisesa Manicaland conduct analysis table format Table A1 httplinkslwwcomQAD A591 compare overall mortality mortality men women HIV status measured study Figure A1 http linkslwwcomQADA591 The demonstrates mortality trends men women unknown HIV status closely match overall mortality trends suggest strong selection bias HIV status information datasets uMkhanyakude site mortality rates men women unknown HIV status consistently different prolonged period time In case lower overall mortality rate suggesting HIVnegative individuals likely HIV status unknown study The mortality rates HIVpositive men women availability treatment exceeded 100 thousand clear upwards downwards trend Fig 2 Modest mortality declines year local introduction ART exception The clearly visible Mortality trends antiretroviral therapy era Africa Reniers et al S539 illustration Masaka Mortality declines pronounced period ART rolled health facilities located study sites Compared preART years adult mortality exceed 58 study sites The mortality rate HIVpositive women Masaka declined 1047 95 CI 7131538 year 2000 167 95 CI 84334 2011 total decline 84 Table A1 httplinkslwwcomQADA591 reductions total In 2011 allcause death rates HIVpositive women ranged 117 Karonga 95 CI 61 225 227 thousand uMkhanyakude 95 CI 191271 ones men varied 133 Masaka 95CI 50353 517 thousand Kisesa 95CI 2581033 mortality HIV positives Rapid falls contributed decline overall adult mortality rates In 2003 ranged 82 Kisesa 95 CI 62107 205 Kisumu 95 CI 191220 thousand women 101 Kisesa 95 CI 79130 235 uMkhanyakude 95 CI 211 261 thousand men By 2011 adult female mortality rates ranged 29 Kisesa 95 CI 19 45 99 uMkhanyakude 95 CI 87113 thousand Male adult death rates low 46 thousand Masaka 95 CI 2972 The highest observed value men 125 thousand uMkha nyakude 95 CI 109144 The results presented Fig 2 Table A1 httplinkslwwcomQADA591 suggestive clear trends mortality rates HIVnegative individuals Figure 3 shows decline mortality HIV positives started treatment PLHIV record treatment initiation The mortality rates men women started ART high ﬁrst years ART available study sites In subsequent years level trend mortality rates comparable treatment status categories uMkhanyakude study site consistent relatively large differences mortality HIV positives ART The assessment trends mortality rates HIV positive men women extended Table 2 contains sitespeciﬁc estimates mortality hazard ratios parametric survival models The auxiliary parameter Weibull model p captures rising mortality risk age More pertinent current discussion change ageadjusted mortality rates time Separate models ﬁtted preART postART period indicate ageadjusted mortality rates PLHIV started declining local introduction ART hazard ratios calendar year preART period signiﬁcantly smaller 1 The coefﬁcients postART period indicative average annual decline mortality hazard ranging 13 Kisesa hazard ratio 087 95 CI 08392 38 Kisumu hazard ratio 062 95 CI 059065 PreART mortality rates HIV positive men women comparable gender differences pronounced following introduction treat ment Gender differences statistically signiﬁcant ﬁve seven study sites postART era Karonga Kisesa Kisumu Rakai uMkhanyakude female advantage increases time study sites shown Rakai uMkhanyakude interaction sex calendar year Table 2 formalizes comparison adult mor tality rates HIV positives initiated ART HIV positives record treatment The mortality levels trends groups generally comparable early years local ARTavailability important exception In study sites available data mortality hazard signiﬁcantly elevated patients accessed treatment early rollout stages The highest ratio mortality hazards observed Kisumu hazard ratio 623 95 CI 468829 In later years mortality hazard patients started treatment higher uMkhanyakude lower Rakai signiﬁcantly different Kisumu Masaka Discussion results demonstrate large impact AIDS Our treatment programmes adult mortality eastern southern Africa In study sites mortality HIV positives relatively stable signs mortality decline prior local introduction ART This decline result increased efforts treat opportunistic infections patients receiving treatment medical facilities outside actual study sites However local rollout ART sizable sustained effect All study sites witnessed average annual reductions mortality hazards HIVpositive adults excess 10 total mortality declines following expansion ART vary 58 84 The largest mortality reduction recorded Kisumu mortality rates 2008 year following introduction ART exceptionally high probably associated postelectoral violence interruption medical services Despite strong mortality reductions PLHIV study sites morality rates HIV positive adults 24 66 times higher HIV negatives sexes combined room underlines improving ART coverage impact S540 AIDS 2014 Vol 28 Suppl 4 A S R e d u k y n h k M u A G U k R A G U k s M M Z I d n l c n M N E K u m u s K Z A T s e s K W A M g n o r K e d o c y r t n u o C e t s y d u t S n o s s e r g e r l l u b e W l v r e t n e c n e d ﬁ n o c 5 9 d n s o t r d r z h s l u d v d n e v t s o p V I H n y t l t r o m e s u c l l A 2 e l b T 4 0 0 2 D N D N D N D N 3 0 0 2 0 0 0 2 3 0 0 2 0 0 0 2 4 0 0 2 0 0 0 2 3 1 1 8 9 0 5 0 1 0 0 1 8 7 0 8 8 0 6 1 1 3 0 1 9 0 1 9 1 1 6 8 0 1 0 1 1 3 1 3 7 0 8 9 0 2 2 1 7 8 0 3 0 1 S N S N S N 5 1 2 8 4 1 9 7 1 6 2 2 8 1 1 4 6 1 1 5 2 4 8 1 5 1 2 5 7 1 3 5 6 6 7 2 9 8 8 1 9 2 0 4 3 8 5 D N D N D N D N 4 0 0 2 0 0 0 2 6 0 1 4 8 0 5 9 0 3 6 1 2 8 0 6 1 1 S N 9 0 3 5 8 1 9 3 2 8 6 8 3 3 1 D N D N D N D N e g n h c l u n n r e y r d n e l C d o r e p T R A e r P f e r n e m o W e l M r e y r d n e l c x e l m n o t c r e t n I e g p s h t e D N 5 8 0 0 8 0 3 8 0 8 7 0 2 7 0 5 7 0 4 8 0 6 7 0 0 8 0 7 8 0 3 8 0 5 8 0 5 6 0 9 5 0 2 6 0 2 9 0 3 8 0 7 8 0 9 9 0 5 7 0 6 8 0 e g n h c l u n n r e y r d n e l C 1 1 0 2 5 0 0 2 0 1 0 2 4 0 0 2 1 1 0 2 4 0 0 2 0 1 0 2 5 0 0 2 1 1 0 2 8 0 0 2 1 1 0 2 5 0 0 2 1 1 0 2 6 0 0 2 d o r e p T R A t s o P 8 4 1 0 9 0 6 1 1 5 1 1 6 8 0 9 9 0 4 3 1 8 8 0 9 0 1 5 1 1 3 9 0 3 0 1 9 3 2 2 9 1 4 1 2 5 6 1 1 0 1 9 2 1 1 4 2 4 1 1 6 6 1 f e r n e m o W n e M 4 1 1 4 0 1 9 0 1 8 1 1 5 0 1 1 1 1 S N 1 5 3 6 0 1 6 5 1 4 2 1 3 9 1 9 3 1 9 2 1 6 2 0 1 9 0 9 4 0 8 5 0 7 6 0 4 0 6 0 6 1 7 7 1 1 8 0 1 1 3 0 2 1 S N D N D N S N 9 2 8 8 6 4 0 3 1 7 8 0 3 2 6 7 0 1 S N D N D N S N D N 5 6 2 0 2 1 8 7 1 r e y r d n e l c x e l m n o t c r e t n I f e r T R A f o d r o c e r o N y l r e e t l T R A T R A d H d H 4 3 2 8 9 1 5 1 2 3 2 2 3 7 1 7 9 1 1 0 2 3 2 1 7 5 1 9 2 2 6 8 1 6 0 2 3 6 1 5 2 1 3 4 1 9 6 2 9 7 1 9 1 2 2 7 2 9 0 1 2 7 1 9 2 1 2 1 3 3 6 1 5 3 5 5 8 0 2 1 3 1 8 1 8 5 3 4 2 8 6 6 0 4 1 3 9 1 3 1 7 4 3 1 8 8 4 1 6 6 2 2 7 6 1 1 1 1 e g p s h t e D N T R A e r P T R A f o n o t c u d o r t n I l c o l e h t e r o f e b s y e v r u s o r e s V H d e s b n o t l u p o p d e t c u d n o c t h t s e t s y d u t s e h t o t d e t c r t s e r s d o r e p T R A e r p e h t f o s s y l n e h T s l e d o m n o s s e r g e r c ﬁ c e p s d o r e p d n c ﬁ c e p s e t s m o r f s e t m t s E s r e b m u n e v t u c e s n o c h t w d e d o c e r s r e y r d n e l c g n w o l l o f e h t e l b l v y l l c o l e d m t s r ﬁ s w T R A n e r e h w r e y e h t h t w g n t r t s 0 d e d o c l l e r t u b d o r e p T R A t s o p e h t r o f s e s y l n e h t o t e t u b r t n o c e l b l v e r e h w s r e y e w b b m Z M Z I d n g U A G U n z n T Z A T c r f A h t u o S A S R y r o g e t c e c n e r e f e r f e r s t n e c ﬁ f e o c e t m t s e o t t d o n D N w l M W A M y n e K N E K y p r e h t l r v o r t e r t n T R A Mortality trends antiretroviral therapy era Africa Reniers et al S541 Gender differences mortality rates PLHIV started appear treatment rolled The estimated mortality hazards men signiﬁcantly higher ﬁve seven study sites increasing time ﬁve sites Our results corroborate earlier ﬁndings women beneﬁtted expansion treatment programmes higher uptake ART better treatment outcomes Despite successful engagement women HIV care treatment programmes premature conclude created new gender disparity men disadvantaged First unclear larger mortality reductions HIVpositive women reversed burden HIV terms life years lost HIV Second lower uptake treatment men imply female partners protected infection male partners HIVpositive women In words gender disparities utilization HIV services sustain previously observed gender disparities number new infections generally higher women In study sites mortality trend PLHIV started ART comparable trend treatment This good indication programmes increasingly successful ensuring timely transitions cascade HIV care treatment PLHIV initiate treatment earlier treatment failures reduced importantly pretreatment mortality declines advanced disease selected treatment leaving increasingly healthy notonART population Other factors changes treatment eligibility criteria availability better drugs complement enhance pattern Despite broad similarities mortality trends PLHIV initiated treatment couple notable differences First mortality PLHIV treatment rollout phase generally higher probably PLHIV began treatment soon locally available advanced disease progression time initiation Second couple sites uMkhanyakude lesser extent Karonga mortality PLHIV started ART continues higher record treatment initiation This indicate linkage care efﬁcient settings lowering pretreatment mortality mortality following treatment initiation higher reasons The population perspective offered ALPHA Network data invaluable attribute studying impact treatment scaleup region close monitoring HIV status services uptake vital events practically feasible relatively small populations come limitations An cited drawback demographic surveillance sites lack generalizability consistency ﬁndings study sites strengthens belief results driven particularities study site including variations data collection protocols Small populations typically affected high levels mobility study sites previous work demonstrated association HIV status 2931 How relationships changed following expansion treatment programmes clear reserve subject future inquiry Acknowledgements This study possible support Wellcome Trust 085477Z08Z Bill Melinda Gates Foundation BMGF OPP1082114 Conﬂicts There conﬂicts References 1 Mills EJ Bakanda C Birungi J Chan K Ford N Cooper CL et al Life expectancy persons receiving combination antiretrovir al therapy lowincome countries cohort analysis Uganda Ann Intern Med 2011 155209216 Johnson LF Mossong J Dorrington RE Schomaker M Hoffmann CJ Keiser O et al Life expectancies South African adults starting antiretroviral treatment collaborative analysis cohort studies PLoS Med 2013 10e1001418 2 3 Brinkhof MW Boulle A Weigel R Messou E Mathers C Orrell C et al Mortality HIVinfected patients starting antiretro viral therapy subSaharan Africa comparison HIV unrelated mortality PLoS Med 2009 6e1000066 4 Rosen S Fox MP Retention HIV care testing treatment subSaharan Africa systematic review PLoS Med 2011 8e1001056 5 Rosen S Fox MP Gill CJ Patient retention antiretroviral therapy programs subSaharan Africa systematic review PLoS Med 2007 4e298 6 Geng EH Emenyonu N Bwana MB Glidden DV Martin JN Samplingbased approach determining outcomes patients lost followup antiretroviral therapy scaleup programs Africa JAMA 2008 300506507 Jahn A Floyd S Crampin AC Mwaungulu F Mvula H Munthali F et al Populationlevel effect HIV adult mortality early evidence reversal introduction antiretroviral therapy Malawi Lancet 2008 37116031611 7 8 Bor J Herbst AJ Newell ML Barnighausen T Increases adult life expectancy rural South Africa valuing scaleup HIV treatment Science 2013 339961965 9 Gargano JW Laserson K Muttai H Odhiambo F Orimba V AdamuZeh M et al The adult population impact HIV care antiretroviral therapy resource poor setting 2003 2008 AIDS 2012 2615451554 10 Ghys PD Zaba B Prins M Survival mortality people infected HIV low middle income countries results extended ALPHA network AIDS 2007 21S1S4 11 Todd J Wringe A Floyd S Zaba B Antiretroviral therapy subSaharan Africa evidence need uptake impact communitybased cohort studies Trop Med Int Health 2012 17e1e2 12 Todd J Slaymaker E Zaba B Mahy M Byass P Measuring HIVrelated mortality ﬁrst decade antiretroviral therapy subSaharan Africa Glob Health Action 2014 7 24787 S542 AIDS 2014 Vol 28 Suppl 4 13 Reniers G Araya T Davey G Nagelkerke N Berhane Y Coutinho R et al Steep declines populationlevel AIDS mortality following introduction antiretroviral therapy Addis Ababa Ethiopia AIDS 2009 23511518 14 Braitstein P Boulle A Nash D Brinkhof MWG Dabis F Laurent C et al Gender use antiretroviral treatment resourceconstrained settings ﬁndings multicenter col laboration J Womens Health Larchmt 2008 174755 15 Staveteig S Wang S Head SK Bradley SEK Nybro E Demographic patterns HIV testing uptake subSaharan Africa DHS Comparative Reports No 30 Calverton Maryland USA ICF International 2013 Available httpdhsprogram compubspdfCR30CR30pdf 16 Muula AS Ngulube TJ Siziya S Makupe CM Umar E Prozesky HW et al Gender distribution adult patients highly active antiretroviral therapy HAART Southern Africa systema tic review BMC Public Health 2007 763 17 Druyts E Dybul M Kanters S Nachega J Birungi J Ford N et al Male sex risk mortality individuals enrolled antiretroviral therapy programs Africa systematic review metaanalysis AIDS 2013 27417425 18 Cornell M Schomaker M Garone DB Giddy J Hoffmann CJ Lessells R et al Gender differences survival adult patients starting antiretroviral therapy South Africa multi centre cohort study PLoS Med 2012 9e1001304 19 Auld AF EttiegneTraore V Zanga Tuho M Mohamed F Azih C Mbofana F et al Differences HIVinfected men women antiretroviral therapy outcomes african coun tries 20042012 MMWR Morb Mortal Wkly Rep 2013 62 946952 20 Hawkins C Chalamilla G Okuma J Spiegelman D Hertzmark E Aris E et al Sex differences antiretroviral treatment outcomes HIVinfected adults urban Tanzanian setting AIDS 2011 2511891197 21 May M Boulle A Phiri S Messou E Myer L Wood R et al Prognosis patients HIV1 infection starting antiretro viral therapy subSaharan Africa collaborative analysis scaleup programmes Lancet 2010 376449457 22 Jahn A Crampin AC Glynn JR Mwinuka V Mwaiyeghele E Mwaﬁlaso J et al Evaluation villageinformant driven demographic surveillance Karonga Northern Malawi Demogr Res 2007 16219248 23 Tanser F Hosegood V Barnighausen T Herbst K Nyirenda M Muhwava W et al Cohort Proﬁle Africa centre demographic information ACDIS populationbased HIV survey Int J Epidemiol 2008 37956962 24 Odhiambo FO Laserson KF Sewe M Hamel MJ Feikin DR Adazu K et al Proﬁle KEMRICDC Health Demo graphic Surveillance SystemWestern Kenya Int J Epidemiol 2012 41977987 25 Asiki G Murphy G NakiyingiMiiro J Seeley J Nsubuga RN Karabarinde A et al The general population cohort rural southwestern Uganda platform communicable noncommunicable disease studies Int J Epidemiol 2013 42 129141 26 Floyd S Molesworth A Dube A Crampin AC Houben R Chihana M et al Underestimation HIV prevalence surveys people know status ways reduce bias AIDS 2013 27233242 27 Nyirenda M Zaba B Barnighausen T Hosegood V Newell ML Adjusting HIV prevalence survey nonresponse mortality rates application method surveil lance data rural South Africa PloS One 2010 5e12370 28 PyneMercier LD JohnStewart GC Richardson BA Kagondu NL Thiga J Noshy H et al The consequences postelection violence antiretroviral HIV therapy Kenya AIDS Care 2011 23562568 29 Anglewicz P Migration marital change HIV infection Malawi Demography 2012 49239265 30 Clark SJ Collinson MA Kahn K Drullinger K Tollman SM Returning home die circular labour migration mortality South Africa Scand J Public Health Suppl 2007 693544 31 Nunn AJ Wagner HU Kamali A KengeyaKayondo JF Mulder DW Migration HIV1 seroprevalence rural Ugandan population AIDS 1995 9503506